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Background—Gene expression signatures have proven to be useful tools in many cancers to
identify distinct subtypes of disease based on molecular features that drive pathogenesis, and to
aid in predicting clinical outcomes. However, there are no current signatures for kidney cancer
that are applicable in a clinical setting.
Objective—To generate a signature biomarker for the clear cell renal cell carcinoma (ccRCC)
good risk (ccA) and poor risk (ccB) subtype classification that could be readily applied to clinical
samples to develop an integrated model for biologically defined risk stratification.
Design, setting, and participants—A set of 72 ccRCC sample standards was used to develop
a 34-gene classifier (ClearCode34) for assigning ccRCC tumors to subtypes. The classifier was
applied to RNA-sequencing data from 380 nonmetastatic ccRCC samples from the Cancer
Genome Atlas (TCGA), and to 157 formalin-fixed clinical samples collected at the University of
North Carolina.
Outcome measurements and statistical analysis—Kaplan-Meier analyses were
performed on the individual cohorts to calculate recurrence-free survival (RFS), cancer-specific
survival (CSS), and overall survival (OS). Training and test sets were randomly selected from the
combined cohorts to assemble a risk prediction model for disease recurrence.
Results and limitations—The subtypes were significantly associated with RFS (p < 0.01),
CSS (p < 0.01), and OS (p < 0.01). Hazard ratios for subtype classification were similar to those of
stage and grade in association with recurrence risk, and remained significant in multivariate
analyses. An integrated molecular/clinical model for RFS to assign patients to risk groups was
able to accurately predict CSS above established, clinical risk-prediction algorithms.
Conclusions—The ClearCode34-based model provides prognostic stratification that improves
upon established algorithms to assess risk for recurrence and death for nonmetastatic ccRCC
patients.
Patient summary—We developed a 34-gene subtype predictor to classify clear cell renal cell
carcinoma tumors according to ccA or ccB subtypes and built a subtype-inclusive model to
analyze patient survival outcomes.
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1. Introduction
The majority of renal cell carcinoma (RCC) or kidney cancer patients have the clear cell
RCC (ccRCC) subtype. Although extensive effort has been devoted to identifying molecular
biomarkers for RCC, there are few validated markers that aid disease prognosis, and none
are used routinely in clinical practice [1–6]. Thus, transcriptional biomarkers present a
potentially target-rich environment toward the goal of improving our understanding of
underlying ccRCC biology.
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Recently, we identified two subtypes of clear cell RCC, ccA and ccB, based on patterns of
differential gene expression, that revealed distinct biologic signatures [7]. These subtypes
appear to provide prognostic information, with tumors classified as ccA associated with
significantly better survival compared to ccB in a retrospective cohort [7]. The ccA/ccB
classification was subsequently validated in a meta-analysis of 480 ccRCC tumors,
suggesting this profile may have value for risk stratification [8].
Building on this foundation, in the present study we demonstrate the utility of a novel tool to
identify the ccA and ccB groups in ccRCC. This molecular tool comprises a 34-gene
expression signature (ClearCode34) and an accompanying protocol for ccA/ccB
classification. Clinical utility of the classifier is demonstrated by (1) accurate and
reproducible classification of ccRCC tumors into ccA and ccB molecular subtypes,( 2)
validation of prognostic classification, (3) adaptation to clinical samples in the form of
formalin-fixed paraffin-embedded (FFPE) tissues, and (4) constructing a more precise
unified model of ccRCC subtype and standard clinical variables to assign individual ccRCC
patients into clinically informative risk categories.
2. Patients and methods
2.1. Patients and clinical samples
The ccRCC samples (n = 95) previously analyzed by gene expression microarray were
clustered to define the ccA and ccB classifications [7]. Of these, 72 were chosen as
references to develop the 34-gene panel based on concordant subtype classifications
determined by two methods: logical analysis of data and ConsensusCluster [7–9] (Fig. 1a).
Prognostic assessment of ClearCode34 was performed using RNA-sequence data of the
Cancer Genome Atlas (TCGA). Median follow-up for this cohort was 38 mo (range: 0–113
mo), with seven patients having no follow-up. Clinical data (last modified August 23, 2013)
were downloaded from TCGA Data Portal [10]. Expert members of TCGA Analysis
Working Group performed pathologic re-evaluation, and cases not definitively representing
clear cell histology were excluded from further analysis [11]. Recurrence and survival data
were taken from TCGA Biotabs database, with appropriate permissions, with
supplementation by the clinical TCGA working group database (version dated April 11,
2013) [10].
Clinical utility of ClearCode34 was performed using randomly selected specimens collected
between 1992 and 2010 at the University of North Carolina (UNC) from patients with
nonmetastatic ccRCC, and stored in the pathology archive as formalin-fixed paraffin-
embedded (FFPE) blocks. Median follow-up for this UNC cohort was 54 mo (range: 3–232
mo). Stage was reclassified using the American Joint Committee on Cancer’s Cancer
Staging Manual, 7th edition (AJCC-7) for all cases preceding 2010 and an expert
genitourinary oncologist and an expert surgical pathologist verified clinical and pathologic
variables.
Only patients with nonmetastatic disease at the time of nephrectomy were used for the study.
This did include a small number of patients with T4 lesions and who had extensive local
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disease classified by AJCC-7 as stage IV but M0 with regard to distant metastasis. No
patients received systemic therapy for ccRCC before nephrectomy or prior to clinical
recurrence. All samples and data were obtained with appropriate institutional review board
approvals.
2.2. The Cancer Genome Atlas data analysis
TCGA RNA sequence data were normalized to the upper quartile of normal counts. For
analysis, the data were log-transformed (base 2) and genes were median centered.
2.3. Formalin-fixed paraffin-embedded sample preparation
UNC cohort FFPE samples were sliced (5–7 μm thick) onto slides or prepared as scrolls 10–
20 μm thick. The surface area of the tissue sectioned was a minimum of 1 cm2. Xylene was
added and washed twice with 100% ethanol. Pellets were suspended in 10 mM 2-(N-
morpholino) ethanesulfonic acid pH 6.5 or Proteinase K digest buffer (Qiagen Gaithersburg
Inc, Gaithersburg, MD, USA) with 0.5% SDS and 5 μl Proteinase K (20 mg/ml).
Suspensions were incubated (55°C), Proteinase K inactivated (80°C), and supernatant
collected.
2.4. NanoString analysis
The UNC genomics core processed 5 μl lysate or 100 ng RNA for hybridization against
NanoString probes (NanoString Technologies Inc, Seattle, WA, USA) [12],
posthybridization in the nCounter Prep Station, and data collection with the nCounter digital
analyzer (NanoString Technologies Inc, Seattle, WA, USA). Sample-specific background
was subtracted using values from included negative controls. Data were normalized using
the geometric mean of housekeeping genes and log transformed (base 2). See the
Supplement for methods details.
2.5. Development of a gene expression classifier of ccA or ccB
To develop a minimal gene set classifier for assigning ccA or ccB subtype, prediction
analysis of microarray (PAM) [13], a centroid-based classification algorithm, was applied to
the microarray reference data (Fig. 1). PAM was used due to its reproducibility in subtype
classification compared to other centroid-based prediction methods [14]. We used a list of
genes (Supplemental Table 1) that encompassed those previously associated with ccA/ccB
classification [7], genes differentially expressed between the ccA/ccB subtypes using
significance analysis of microarrays, and other published markers [2–6]. Ninety-four percent
of the tumors were classified correctly (68 of 72) using a PAM model of 34 genes (Table 1)
based on nearest centroids. This gene list was labeled ClearCode34.
Cross-validation (random 10% left out in each of 50 cycles) was applied to the microarray
reference set to evaluate the accuracy of the classifier and anticipated performance on
independent sample cohorts. Unsupervised clustering and ConsensusCluster [9] were used to
further assess assignment accuracy by the minimized gene panel in the microarray standard
set by comparing PAM-derived subtype assignments with those determined previously [7].
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All continuous variables were described with the median and range values. Recurrence, or
relapse, was defined as the date from nephrectomy to the date that recurrence or metastasis
was detected by imaging or pathology report. Cancer-specific survival (CSS) was defined as
the time from nephrectomy to death resulting specifically from ccRCC; patients who
remained alive, died of other reasons, or had unknown causes of death were censored for
this outcome at the date of last follow-up or death. Overall survival (OS) was defined as the
time from the nephrectomy to death of any cause. The probability of death or recurrence was
determined by using the Kaplan-Meier method, with log-rank tests assessing the differences
between the groups. CSS was analyzed using the competing risk method (cmprsk R
package; R Project for Statistical Computing, Vienna, Austria). Cox proportional hazard
models and likelihood ratio using OS, CSS, and recurrence outcomes were used to compare
competing survival models. ccRCC subtype, Fuhrman grade, and stage were modeled as
additive predictors of outcome. Cox proportional hazard models were used to estimate
hazard ratios (HRs) and 95% confidence intervals (CIs).
2.7. Developing a relapse risk model
The TCGA and UNC cohorts were combined to develop a risk model for tumor relapse (Fig.
2). The combined cohort consisted of 531 patients, after removing six patients with missing
grade information. The combined cohort was randomly split into two sets of equal size for
use as training and evaluation cohorts for the prognostic model. Samples were used only
once for either the training or test set. A multivariable Cox model with ccA/ccB subtype,
stage, and Fuhrman grade as additive terms was fit with Ridge regression. Tenfold cross-
validation was performed in the training set to optimize the penalty parameter. A final model
was fit to the entire training set using the optimized parameters and then applied to the test
set. See the Supplement for details in identifying risk groups and assigning cases.
3. Results
3.1. Subtype comparison for prognosis and recurrence in the Cancer Genome Atlas data
set
To evaluate the prognostic utility of ClearCode34 for ccA and ccB ccRCC tumors, Kaplan-
Meier analysis was used to assess tumor recurrence and survival rates by subtype
assignment in tumor samples from 380 nonmetastatic ccRCC patients from the TCGA data
set (Table 2). Univariate analysis revealed ccB patients experienced tumor recurrence earlier
and more frequently than ccA (HR: 2.3; 95% CI, 1.6–3.3; p = 4.3 × 10−6) (Fig. 3a).
Moreover, ccB patients had almost three times the risk of death from disease (HR, 2.9; 95%
CI, 1.6–5.6; p = 0.0005) and more than two times the risk of death from any cause compared
to ccA (HR: 2.4; 95% CI, 1.6–3.7; p = 2.3 × 10−5) (Fig. 3b and 3c). Competing risk analysis
further validated the differences in survival between the subtypes, which showed their
specificity as prognostic tools for ccRCC (CSS, p = 0.002; OS, p = 0.037).
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3.2. Biomarker validation in an independent cohort
Since ClearCode34 demonstrated prognostic value in the TCGA cohort from known clinical
samples, we next validated the classifier in an independent group of clinical specimens using
the NanoString platform. Applying the classifier to a cohort of 157 nonmetastatic ccRCC,
archived FFPE samples (Table 3), 69 samples were assigned as ccA subtype and 88 as ccB,
and, again, the subtype classifications followed survival patterns seen previously (Fig. 4). In
this cohort, ccB cases experienced tumor relapse after nephrectomy more frequently (HR:
2.1; 95% CI, 1.3–3.4; p = 0.001) (Fig. 4a) and had higher risk of both cancer-specific
mortality (HR: 3.0) (Fig 4b) and overall mortality (HR: 2.2) (Fig. 4c) compared to patients
classified as ccA. In addition, cancer-specific deaths (p = 0.013), but not overall deaths (p =
0.344), remained significant between subtypes after competing risk analysis.
3.3. Prognostic risk models for recurrence in patients with nonmetastatic clear cell renal
cell carcinoma
We next sought to determine if a recurrence risk model encompassing both ClearCode34
ccRCC subclassification along with stage and Fuhrman grade could be used to enhance the
assessment of patient risk. A Cox model for recurrence was assembled using a combined
cohort including both the TCGA and UNC cohorts. In the final model, subtype classification
(p = 0.0009), Fuhrman grade (I/II vs greater; p < 0.0001), and stage (stage I vs greater; p =
0.0007) were found to be significant independent variables for predicting recurrence-free
survival (RFS) (Supplemental Table 2). Likelihood ratios verified that subtype status was a
prognostic factor even after adjustment for stage and Fuhrman grade. A training set was
randomly selected from the combined cohort and used to train the risk prediction model,
focusing on recurrence. Thresholds for identifying patients for high probability of recurrence
within 5 yr following surgical resection were determined by Ridge regression, fit to the
training set, and used to stratify low-, intermediate-, and high-risk groups of relapse (p =
3.04 × 10−9) (Fig. 5a). The high- and intermediate-risk groups had a median time to
recurrence of 23 and 85 mo, respectively. A 50% survival probability failed to be reached by
the low-risk group. Similarly, the three risk groups showed similar survival trends for
cancer-specific death after applying the thresholds determined for RFS (p = 2.03 × 10−8)
(Fig. 5b).
Furthermore, we compared our risk assessment tool with existing clinical nomograms to
predict death from ccRCC, using multivariate and co-occurrence index (C-index) analysis
(Fig. 5c–5f). Our analyses show superiority in assessing risk of ccRCC death by C-index
analysis using prognostic classification (ClearCode34 model) compared to the University of
California, Los Angeles (UCLA) Integrated Staging System (UISS) [15] and the Mayo
Clinic Stage, Size, Grade, and Necrosis (SSIGN) score [16]. Not only did our model better
predict disease-specific events (Fig. 5c and 5e), but it also was additive independently of
both UISS (UISS, model) and SSIGN (SSIGN, model) (Fig. 5d and 5f), indicating added
prognostic information for disease-specific outcomes. Interestingly, subtype classification
alone outperformed the UISS algorithm (data not shown). Thus, using ClearCode34
enhances risk stratification, which may guide future clinical planning regarding patient
surveillance and adjuvant therapy.
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We developed ClearCode34 to adapt the ccA/ccB ccRCC classification to the real world of
clinical practice. In this study, we used NanoString to measure expression profiles in clinical
specimens. This modality is an emerging, highly reproducible, and low-cost technology for
gene expression biomarkers. This work demonstrated that molecular phenotyping using
ClearCode34 has added value to predicting risk above standard clinical and pathologic
variables as well as standard ccRCC risk algorithms and may, thereby, enhance patient-
treatment planning.
TCGA cohort allowed testing of the prognostic value of ClearCode34 in an independent data
set, revealing that ccA and ccB were significantly associated with multiple survival end
points, which was also observed in the UNC cohort derived from FFPE tissues. We pooled
TCGA and UNC cohorts to build a risk predictive model that captures the time period
during which the majority of recurrences occur. There remains a potential failure to capture
late recurrences, but these tend to be uncommon and typically have a more favorable
outcome [17,18]. Multivariate analysis for risk of tumor recurrence suggested that the risk
prediction model including subtype, stage, and Fuhrman grade provided the best fit given
the available variables. Moreover, the model was shown to be a better predictor for CSS
than the UISS and SSIGN score, demonstrating the proficiency of this molecular model over
standard clinical algorithms. Furthermore, performance status, a key component of the UISS
algorithm, is highly subjective, and rarely reported in clinical records. In addition, necrosis
is only available upon gross examination and cannot be accurately assessed on biopsy
specimens. Although this study did not examine biopsy specimens, we have observed that
this biomarker can be applied to biopsy tissue, which could be used to provide essential
presurgical risk information. Based on a 2012 study exploring genetic heterogeneity [19],
we must be prepared to consider that primary tumors may be genetically divergent from
metastases, which may present a challenge in developing tools for predicting the behavior of
metastatic disease.
The primary value of this proposed classification system would be for clinicians caring for
patients who present with nonmetastatic tumors, seeking guidance regarding postsurgical
management, especially as adjuvant therapy is emerging. Although surveillance guidelines
exist following nephrectomy, the extent of monitoring is applied in a variable fashion. The
availability of an integrated risk-prediction tool may allow guideline refinement for more
uniform patient management. Stage and grade remain the most highly significant predictors
of risk, given the exceptionally low risk of metastasis with T1a disease, and the
exceptionally high risk with T3b/T4 stage. However, it is important to risk stratify patients
with intermediate stage tumors, which encompasses an enormous range of both local tumor
features and risk.
Gene expression-based tools are widely used in the classification, risk assessment, and
therapeutic selection of diseases, such as breast cancers [14,20,21], and are becoming
standard for the classification of diffuse large B-cell lymphoma [22] as well as colon cancer
[23,24]. Other expression-based systems have examined ccRCC and have demonstrated
patterns associated with risk [25]. Because several individual transcripts had previously been
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associated with risk in ccRCC [1–6], we specifically incorporated those features in our
model and many were included in the final ClearCode34 code set, validating their relevance
in ccRCC risk prediction. Future prospective studies, with large cohorts of patients, will be
needed to fully refine the integrated prognostic algorithm.
5. Conclusions
This work presents a novel integration of molecular profiling with standard clinical features
to significantly enhance prognostication in ccRCC, thus defining the subset of patients at
greatest risk for recurrence for risk-stratified patient care.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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A 34-gene subtype predictor effectively classifies clear cell renal cell carcinoma tumors
according to ccA or ccB subtype. The predictor can be used for future analyses involving
risk for developing metastatic disease and cancer-specific outcomes.
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Workflow for biomarker discovery: steps taken to identify the 34 genes that classify ccA
and ccB tumors.
LAD = logical analysis of data.
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Order of analyses to develop and validate the relapse risk model. Diagram of analyses to
validate the efficiency of the biomarkers to classify tumors and predict prognostic outcomes.
TCGA = the Cancer Genome Atlas; UNC = University of North Carolina.
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Tumor classification from the Cancer Genome Atlas (TCGA) shows distinct prognostic
outcomes. Prediction analysis for microarray classified 380 untreated, nonmetastatic clear
cell renal cell carcinoma tumors from TCGA as either ccA or ccB, using the 34-gene
classifier, ClearCode34. Kaplan-Meier curves were used to calculate (a) recurrence-free
survival (RFS), (b) cancer-specific survival (CSS), and(c) overall survival (OS) for ccA and
ccB patients. ccB-typed patients had a median RFS and OS of 53 and 65 mo, respectively,
while patients with ccA-typed tumors had a 50% survival probability of 91 and 94 mo for
RFS and OS, respectively.
HR = hazard ratio; CI = confidence interval.
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Clear cell renal cell carcinoma (ccRCC) classifier recapitulates survival outcomes for
subtypes in clinical cohort. Whole lysates from 157 nonmetastatic, archived ccRCC primary
tumor samples were subjected to NanoString gene expression analysis (NanoString
Technologies Inc, Seattle, WA, USA). Kaplan-Meier plots of the independent cohort using
ClearCode34 show ccB patients have significantly lower probabilities of (a) recurrence-free
survival (RFS), (b) cancer-specific survival (CSS), and (c) overall survival (OS) compared
to ccA.
HR = hazard ratio; CI = confidence interval.
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ClearCode34 prognostic model can evaluate patient risk. A randomized training set of 265
patients from the Cancer Genome Atlas (TCGA) project and clinical cohorts were used to
train a model to identify low-, intermediate-, and high-risk groups for tumor recurrence
using clear cell renal cell carcinoma (ccRCC) subtype status (ccA/ccB), tumor stage, and
histologic Fuhrman grade. The model was applied to the test set (n = 266) to predict (a)
recurrence and (b) cancer-specific death, revealing a highly significant risk profile
integrating clinical and biologic features. (c and e) Co-occurrence index (C-index) and (d
and f) multivariate analysis validated the efficacy of the model using the three risk groups to
predict risk of ccRCC death over the established algorithms University of California, Los
Angeles Integrated Staging System (UISS) and Mayo Clinic Stage, Size, Grade, and
Necrosis (SSIGN) score. Chi-square statistic values resulting from multivariate regression
depict the additive value of the three risk models.
*p < 0.05.
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ccRCC = clear cell renal cell carcinoma.
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Table 2
Patient demographics and clinical characteristics of The Cancer Genome Atlas cohort
Characteristic No. %
Sex
 Male 243 64





 White 330 87
 Black 17 5
 Hispanic 20 5
 Asian 8 2
 Unknown 5 1
Fuhrman grade
 I 6 2
 II 181 48
 III 150 39
 IV 37 10
 Unknown 6 1
Staging (TNM)
 I 216 56
 II 45 12
 III 116 31
 IV 3 1
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Table 3




 Male 94 60





 White 102 65
 Black 44 28
 Hispanic 5 3
 Asian 1 1
 Native American 5 3
Fuhrman grade group
 I 3 2
 II 70 45
 III 70 45
 IV 14 8
Staging (TNM)
 I 78 50
 II 23 14
 III 56 36
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